This Company Just Announced Plans to Develop a Gene Therapy for Type 2A Charcot-Marie-Tooth Disease

According to a story from BioSpace, the genetic medicines company Passage Bio recently announced plans for its sixth program for gene therapy development. The company plans to work with the…

Continue Reading This Company Just Announced Plans to Develop a Gene Therapy for Type 2A Charcot-Marie-Tooth Disease
New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups
truthseeker08 / Pixabay

New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups

According to a story from journals.lww.com, The Lazarex Cancer Foundation and the University of California San Francisco have announced plans to work together on a three year study that will…

Continue Reading New Study Will Investigate Methods to Improve Cancer Trial Participation for Historically Under-Represented Groups

An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show

According to a story from Biotech 365, the biotechnology company Viela Bio announced the publication of critical results from a recent study that tested the company's investigational drug inebilizumab as…

Continue Reading An Experimental Drug Could be Effective for Neuromyelitis Optica, Study Results Show
A Patient Registry is Critical for Advancing Myalgic Encephalomyelitis Research
cpastrick / Pixabay

A Patient Registry is Critical for Advancing Myalgic Encephalomyelitis Research

According to a story from meaction.net, Jaime Seltzer, the Director of Scientific and Medical Outreach at #MEAction, recently spoke at the Third Annual Working Group Meeting on the Molecular Basis…

Continue Reading A Patient Registry is Critical for Advancing Myalgic Encephalomyelitis Research

An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation

According to a story from firstworldpharma.com, the biopharmaceutical company Acceleron Pharma, Inc., recently announced that the company's experimental product candidate sotatercept has earned Orphan Drug designation from the US Food…

Continue Reading An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation
This Drug Could be a Breakthrough for Severe Familial Hypercholesterolemia, But How Much Will it Cost?
jarmoluk / Pixabay

This Drug Could be a Breakthrough for Severe Familial Hypercholesterolemia, But How Much Will it Cost?

According to a story from Forbes, a new drug developed by the company Regeneron has the potential to make a real difference for people with the homozygous form of familial…

Continue Reading This Drug Could be a Breakthrough for Severe Familial Hypercholesterolemia, But How Much Will it Cost?
A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease
katicaj / Pixabay

A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease

According to a story from rheumatology.medicinematters.com, a recent Italian real-world study has provided some evidence that the drug apremilast, which is considered a phosphodiesterase-4 inhibitor, could be a useful treatment…

Continue Reading A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease

The Sudden Closure of Northwestern University’s Stem Cell Therapy Clinic Raises Questions That Remain Unanswered

According to a recent article in The Scientist, Northwestern Medicine’s successful autoimmune and immunotherapy program is winding down and will be closed by the end of the year. The program,…

Continue Reading The Sudden Closure of Northwestern University’s Stem Cell Therapy Clinic Raises Questions That Remain Unanswered
Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis
rawpixel / Pixabay

Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis

According to a story from BioPortfolio, Alexion Pharmaceuticals, Inc. and Eidos Therapeutics, Inc., have recently struck an agreement related to the development and marketing of an experimental treatment for hATTR…

Continue Reading Companies Reach Partnership Agreement Related to an Experimental Treatment for ATTR Amyloidosis

Patients in Mayo Clinic’s RIGHT Study Carried One or More Genetic Variants That May Affect Their Response to Medication

  Pharmacogenomics plays an important role in predicting whether patients will benefit from certain medications or if the medication will cause serious side effects. The process involves the way in…

Continue Reading Patients in Mayo Clinic’s RIGHT Study Carried One or More Genetic Variants That May Affect Their Response to Medication